Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29716173 | 1.00 | RORC (0.40) | RORCAVPR1AESR2USP30NR1H2 | |
| SCHEMBL20502778 | 0.92 | RORC (0.41) | RORCAVPR1AESR2USP30NR1H2 | |
| SCHEMBL30508320 | 0.88 | AVPR1A (0.49) | RORCAVPR1AESR2USP30NR1H2 | |
| SCHEMBL16864998 | 0.87 | AVPR1A (0.40) | AVPR1AESR2NR1H2HDAC1DDB1 | |
| SCHEMBL21788515 | 0.86 | AVPR1A (0.45) | AVPR1AESR2USP30NR1H2HDAC1 | |
| SCHEMBL12097185 | 0.86 | GPR119 (0.42) | AVPR1AESR2NR1H2HDAC1DDB1 | |
| SCHEMBL15505675 | 0.84 | HDAC1 (0.43) | AVPR1AESR2NR1H2HDAC1DDB1 | |
| SCHEMBL17930157 | 0.84 | GPR119 (0.42) | AVPR1AESR2NR1H2 | |
| SCHEMBL29948788 | 0.84 | HDAC1 (0.43) | AVPR1AESR2NR1H2HDAC1DDB1 | |
| SCHEMBL30008913 | 0.83 | AVPR1A (0.53) | AVPR1AESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683723-B1 | SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2016-05-25 | — | — | EP | claimed |
| EP-2683723-A1 | SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | Zoetis LLC (US) | 2014-01-15 | — | — | EP | claimed |
| US-8466115-B2 | Spirocyclic isoxazoline derivatives as antiparasitic agents | ZOETIS LLC (US) | 2013-06-18 | — | — | US | claimed |
| WO-2012120399-A1 | SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-09-13 | — | — | WO | claimed |
| US-20120232026-A1 | SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-09-13 | — | — | US | claimed |
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260070879-A1 | ISOXAZOLINE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2026-03-12 | — | — | US | disclosed |
| US-12497370-B2 | Isoxazoline derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2025-12-16 | — | — | US | disclosed |
| US-12421252-B2 | Spiro (isobenzofuranazetidine) compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4061821-B1 | SPIRO(ISOBENZOFURANAZETIDINE) COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
| US-8466115-B2 | Spirocyclic isoxazoline derivatives as antiparasitic agents | ZOETIS LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466115-B2 | Spirocyclic isoxazoline derivatives as antiparasitic agents | ZOETIS LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466115-B2 | Spirocyclic isoxazoline derivatives as antiparasitic agents | ZOETIS LLC (US) | 2013-06-18 | — | — | US | disclosed |
| WO-2012120399-A1 | SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120232026-A1 | SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232026-A1 | SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012120399-A1 | SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120232026-A1 | SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497370-B2 | Isoxazoline derivatives | CYP3A7, CYP4X1, CYP2A7 | RORC 2059/4885AVPR1A 1048/4885ESR2 2823/4885 |
| US-20260070879-A1 | ISOXAZOLINE DERIVATIVES | CHRM1, CBR3, AFF1 | RORC 3914/4885AVPR1A 411/4885ESR2 1345/4885 |
| US-20120232026-A1 | SPIROCYCLIC ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | REN, AVPR1A, AVPR1B | RORC 340/4885AVPR1A 2/4885ESR2 709/4885 |
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | RORC 646/4885AVPR1A 3867/4885ESR2 742/4885 |
| US-12421252-B2 | Spiro (isobenzofuranazetidine) compounds for the treatment of autoimmune disease | REN, PKD2, PKD1 | RORC 209/4885AVPR1A 425/4885ESR2 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.